Erlotinib and pantoprazole: a relevant interaction or not? - Wikidata - awgldk - TriplyDB

Erlotinib and pantoprazole: a relevant interaction or not?

Erlotinib and pantoprazole: a relevant interaction or not?

http://www.wikidata.org/entity/Q34457467

about

Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.Targeted cancer therapy: interactions with other medicines.Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.Effect of acid suppressants on the efficacy of tyrosine kinase inhibitors in patients with epidermal growth factor receptor-mutated non-small-cell lung cancer.Drug-drug interactions: is there an optimal way to study them?Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.

P2860

Q36092883-347436EA-D4D7-4797-B0FA-5A482E89E5CC Q36713494-B34E416C-F21B-499B-81C2-AACFEC8A1E73 Q37709182-FCC9DF97-7C72-4E78-8B3D-F88C4346B93F Q38817201-90C4B84A-8A05-4F66-BE28-B33B5EF5B3B5 Q38818845-A8B68EFB-C028-43CF-9D9F-54DA000A51EC Q39013343-1713C816-EF90-44C8-8305-351F5C4BC0A9 Q40480137-9FBFEF71-5E96-4DCC-A583-290B3B22B9AC Q41589276-D5895456-7DDA-4DDE-96FA-7007458197BF Q47969048-EEF586DF-9D87-4633-A219-1D1096DAEAE0 Q49909297-1EA83577-4427-4EDA-842B-03851820A4FD Q51746806-E2C5217F-190E-4A70-BAA0-D389D5D9EC4D

P2860

Erlotinib and pantoprazole: a relevant interaction or not?

http://www.wikidata.org/entity/Q34457467

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Erlotinib and pantoprazole: a relevant interaction or not?

@ast

Erlotinib and pantoprazole: a relevant interaction or not?

@en

Erlotinib and pantoprazole: a relevant interaction or not?

@nl

type

label

Erlotinib and pantoprazole: a relevant interaction or not?

@ast

Erlotinib and pantoprazole: a relevant interaction or not?

@en

Erlotinib and pantoprazole: a relevant interaction or not?

@nl

prefLabel

Erlotinib and pantoprazole: a relevant interaction or not?

@ast

Erlotinib and pantoprazole: a relevant interaction or not?

@en

Erlotinib and pantoprazole: a relevant interaction or not?

@nl

P1433

Q34457467-70DE4156-CC1E-4063-B1C4-6C648507BB7F

P1476

Q34457467-23F964C0-F0DD-477F-B19F-05EBB6A628BE

P2093

Q34457467-20A328D2-191B-457E-8FA0-50EC2F49B1B1

Q34457467-447CA5BF-F042-4CFA-BB4F-BF79F11946A9

Q34457467-B8123F8B-EFC0-4ED0-AFBF-DA5A87825BE9

Q34457467-B85D164F-5B81-42DC-A756-05D92DC08703

Q34457467-D36382DA-6B91-419D-ACA4-39025EAD76B3

Q34457467-F66457C0-A301-4493-90B5-B96ED5DE5135

Q34457467-F7737569-A11A-4DB4-B29E-A2373D0C9E8D

P2860

Q34457467-08E54D1C-6408-4F6E-8C9F-F1E968D3FAAD

Q34457467-2032541E-7D40-4FAF-BF2B-8457D5999557

Q34457467-5EAD0215-6634-4FE5-9683-775583D8BCAD

Q34457467-6B8E2A90-3AF2-4831-9CAB-49ABA4A239D3

Q34457467-6CFD6318-008D-4DAB-B9F6-5E52BD7AC383

Q34457467-8C6187B0-F556-4F0E-8F42-A7BFD76A0A4B

Q34457467-BB2B75D6-CFDE-4733-B849-A739A61B2FA7

Q34457467-BC710797-089C-4244-B280-6E5DBC3479C4

Q34457467-F7A5E9D8-B406-4011-899D-20FE280C696D

P304

Q34457467-4B06474D-7E53-4CDD-8F3B-71FB98B2DBB5

P31

Q34457467-0F7BB328-9F1C-4DAC-BBAB-F20A50541462

P356

Q34457467-EC554B2F-15E5-4573-9E07-0417F7F96323

P407

Q34457467-251FEC5E-B28D-46C5-A187-69CE3D88BBD9

P433

Q34457467-D84BC743-D1D8-4CF2-BC48-97345E31B938

P478

Q34457467-5FFF921F-A50B-4D31-90B9-08536636D1BF

P577

Q34457467-256C71DA-9E95-447C-B96E-D09E81F02CB0

P5875

Q34457467-9F299442-3035-491F-9724-1DC775D1265B

P698

Q34457467-E1608EC8-F376-4A39-9F5D-73F6C0B28C6F

P932

Q34457467-08B34452-C863-4F8F-B919-315798918D2C

P356

J.1365-2125.2010.03748.X

P1433

British Journal of Clinical Pharmacology

P1476

Erlotinib and pantoprazole: a relevant interaction or not?

@en

P2093

Gerald H A Staaks

http://www.w3.org/2001/XMLSchema#string

James C Fanggiday

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

Mirte M Malingré

http://www.w3.org/2001/XMLSchema#string

Monique M L Van Der Westerlaken

http://www.w3.org/2001/XMLSchema#string

Nienke A G Lankheet

http://www.w3.org/2001/XMLSchema#string

Rob Ter Heine

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.

Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein.

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.

The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: computer-based simulation (SimCYP) predicts in vivo metabolic inhibition.

A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

P304

908-911

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2010.03748.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49699751

http://www.w3.org/2001/XMLSchema#string

P698

21175447

http://www.w3.org/2001/XMLSchema#string

P932

3014075

http://www.w3.org/2001/XMLSchema#string